Abiopharma

AMC Entertainment Holdings, Inc. Announces Closing of $200 Million Registered Direct Offering of Common Stock

Additional extension of the memorandum of understanding between Delek Israel and HOT Mobile until June 30, 2026

Share Buy Back - Daily Share Buy-Back Notice: Share Buy Back - Daily Share Buy-Back Notice

KKR Announces Intra-Quarter Update

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)Advanced Triple-Negative Breast Cancer (TNBC)

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Jacobs named supplier on UK government construction professional services framework

CMC Reports Third Quarter of Fiscal 2026 Results

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

Results of the general meeting dated 25.6.26